Inclusion Criteria

DISEASE CHARACTERISTICS:

- Diagnosed with advanced hematologic malignancies meeting the following criteria:

- Multiple myeloma

- Received ≥ 2 lines of prior chemotherapy (induction chemotherapy followed
by high-dose chemotherapy and autologous stem cell transplant with or
without maintenance therapy is considered one line of therapy)

- Acute myeloid leukemia

- Acute lymphoblastic leukemia

- Diffuse large B-cell lymphoma

- Hodgkin lymphoma

- Mantle cell lymphoma

- Mature T- and NK-cell neoplasms restricted to the following WHO-defined
entities:

- T-cell prolymphocytic leukemia

- T-cell large granular lymphocytic leukemia

- Aggressive NK-cell leukemia

- Adult T-cell leukemia/lymphoma

- Extranodal NK/T-cell lymphoma (nasal type)

- Mycosis fungoides

- Sézary syndrome

- Primary CD30-positive T-cell lymphoproliferative disorders

- Primary cutaneous anaplastic large cell lymphoma

- Primary cutaneous gamma-delta T-cell lymphoma

- Peripheral T-cell lymphoma (not otherwise specified)

- Angioimmunoblastic T-cell lymphoma

- Anaplastic large cell lymphoma (ALK-positive/ALK-negative)

- Grade 3B follicular lymphoma

- Relapsed following or progressed during standard therapy

- Meeting the following criteria:

- Standard intensive therapy is not feasible

- Current disease state for which there is no standard effective therapy

- Refused standard therapy where no curative option exists

- Measurable disease, defined as the following:

- Myeloma: measurable serum monoclonal protein > 1 g/dL for IgG, or > 0.5 g/dL for
IgA, IgM or IgD, or difference between involved and uninvolved free light chain
levels in serum > 100 mg/L

- Lymphoma: must have ≥ 1 lesion measurable by CT (longest diameter ≥ 15 mm)

- Acute leukemia: ≥ 20% blasts in bone marrow or in peripheral blood (≥ 200/mL
blasts in peripheral blood)

- No HIV-associated lymphoma

PATIENT CHARACTERISTICS:

- WHO performance status 0-2

- Absolute neutrophil count ≥ 1,500/mm³

- Platelet count ≥ 75,000/mm³ (if bone marrow impairment, ≥ 20,000/mm^3)

- Hemoglobin > 80 g/L (if considered to be caused by the underlying hematologic
malignancy or bone marrow impairment, > 80 g/L after transfusion)

- Bilirubin ≤ 1.5 times upper limit of normal (ULN) (if suspected hemolysis, direct
bilirubin ≤ 1.5 times ULN)

- ALT ≤ 2.5 times ULN

- Calculated creatinine clearance > 30 mL/min

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 12 months after
completion of study treatment

- Willing and capable to comply with an oral regimen

- Capable of understanding information given by the investigator on the trial

- Able to adhere and remain in geographic proximity to allow proper staging, treatment,
and followup

- No other non-hematologic malignancy within the past 5 years, except adequately
treated cervical carcinoma in situ or localized nonmelanoma skin cancer

- No known chronic hepatitis B or C infection or known HIV infection

- No serious underlying medical condition (at the judgment of the investigator) which
would impair the ability of the patient to participate in the trial, including any of
the following:

- Active autoimmune disease

- Uncontrolled diabetes

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- Psychiatric disorder

- No myocardial infarction within the past 6 months

- No polyneuropathy > grade 1 significantly interfering with activities of daily living
or painful polyneuropathy

- No known hypersensitivity to trial drugs or hypersensitivity to any other component
of the trial drugs

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No more than 4 prior lines of chemotherapeutic regimens (induction chemotherapy
followed by high-dose chemotherapy and autologous stem cell transplant with or
without maintenance therapy is considered one line of therapy)

- More than 30 days since prior treatment in a clinical trial

- More than 30 days since prior and no concurrent chemotherapy or biologic agents

- For patients with acute leukemia, hydroxyurea may be given up to 48 hours before
first administration of the trial treatment, and low dose cytarabine (up to 20
mg/m^2) and mitoxantrone up to 20 mg up to 14 days before first dosing

- At least 1 week since prior and no concurrent CYP3A4 modulators

- No concurrent other experimental drugs

- No concurrent radiotherapy

- No concurrent antineoplastic therapy with chemotherapeutic or biologic agents